formyl peptide receptor (fpr)

MMK 1 acetate is an agonist of formyl peptide receptor 2 (FPR2), which was previously known as formyl peptide receptor-like 1 (FPRL1) [1].

Ac9-25 acetate is an annexin AI peptide and activates the neutrophil reduced nicotinamide adenine dinucleotide phosphate oxidase through FPR but not through FPRL1.

{Boc}-Phe-Leu-Phe-Leu-Phe ({Boc}-FLFLF) is a selective antagonist of the formyl peptide receptor (FPR) family, effectively inhibiting receptor activity in response to formyl peptides.

Ac9-25 TFA, an N-terminal peptide of Annexin I, functions as a formyl peptide receptor (FPR) agonist, activating neutrophil NADPH oxidase via FPR [1] [2].

{Boc}-Phe-Leu-Phe-Leu-Phe TFA is a selective antagonist of the formyl peptide receptor (FPR) family, effectively inhibiting FPR-mediated actions [1].

HCH6-1 is a competitive Formyl peptide receptor 1 (FPR1) antagonist.

N-Formyl-Nle-Leu-Phe-Nle-Tyr-Lys TFA (For-Nle-Leu-Phe-Nle-Tyr-Lys-OH (TFA)) (For-Nle-Leu-Phe-Nle-Tyr-Lys-OH TFA) is a formyl peptide receptor (FPR) agonist and a potent chemoattractant for human neutrophils, with its radioiodinated form retaining full biological activity.

N-Boc-Phe-Leu-Phe-Leu-Phe (Boc-FLFLF) is a formyl peptide receptor 1 (FPR1) antagonist that increases pain effects and inhibits the antinociceptive activity of annexin. Boc-FLFLF is extensively used in FPR research.

N-Formyl-Nle-Leu-Phe-Nle-Tyr-Lys TFA is a formyl peptide receptor (FPR) agonist.